Research programme: anti-cancer toxin-coupled monoclonal antibodies - Kyto Biopharma

Drug Profile

Research programme: anti-cancer toxin-coupled monoclonal antibodies - Kyto Biopharma

Alternative Names: mAbTCR23

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Kyto Biopharma
  • Class Monoclonal antibodies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral)
  • 05 Mar 2010 Kyto Biopharma signs a licensing agreement with the Research Foundation of the State University of New York (RFSUNY)
  • 07 Dec 2009 This programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top